WASHINGTON – Caught in a vicious circle of spiraling drug imports, the FDA is scrambling to develop the tools and get the authority it needs to ensure the safety of the nation's medicine chest. Read More
F-star GmbH closed on a $21.7 million financing, bringing to more than $49 million the amount raised since the Vienna, Austria-based company was founded in 2006. Read More
Since induced pluripotent stem cells (iPSC) were first described in 2006, researchers have steadily chipped away at the number of transcription factors necessary to generate them. Read More
In 2009 the economy was in a free fall and no one knew when it would hit bottom. Yet an investment officer at a bank took a chance on a high-risk opportunity: a tiny company in New Haven, Conn. Helix Therapeutics LLC's CEO Joseph Catino said the investment officer told him, "I know you. I don't know squat about the technology, but I trust you guys and know you'll do this well." Read More
Seattle Genetics Inc., of Bothell, Wash., announced that 10 programs using the company's antibody-drug conjugate (ADC) technology are now in clinical development across its 11 current ADC collaborations. That includes two additional ADC programs for which investigational new drug applications were recently submitted to the FDA by Genentech, a member of the Roche Group, of Basel, Switzerland, triggering milestone payments to Seattle Genetics. Read More
